Conversations in Healthcare

Conversations in Healthcare

By ClarivateNewsBusiness News
Download on the App Store

Conversations in Healthcare episodes

  • The pandemic, politicians and science
    In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Baroness Susan Greenfield, founder and CEO of Oxford-based start-up Neuro-bio. Susan and Mike discuss the impacts of COVID-19 in the workplace and how the new stay-at-home policy has put a pause on projects. As a member of the House of Lords, Susan was also able to explore and share her views on the dynamics between politicians and science.

    Hosted on Acast. See acast.com/privacy for more information.

    28 min
  • COVID-19 continues to disrupt patient care
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to John Jaeger, a partner at DRG on how COVID-19 is disrupting access to care. John talks us through the results from a recent physician survey, about current limitations on access to treatment including how patients are responding to the shift from in-facility treatment to home-administered treatments. John and Mike also discuss the implications of the “warehousing” effect that will take place and continue to disrupt the space caused by patients waiting to receive care or delaying treatment until the pandemic eases. They also speculate which of these changes may become permanent fixtures post pandemic.

    Hosted on Acast. See acast.com/privacy for more information.

    27 min
  • The effects of COVID-19 on worldwide oncology clinical trials
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Steve Fruchtman, President and CEO of Onconova Therapeutics Inc, about how the reallocation of resources within cancer centres around the world due to COVID-19. Steve talked us through the impacts on their early and late stage lead programs which includes short term restrictions such as accessing review data, as well as longer-term impacts including additional monitoring and testing for patients on haematology and oncology trials. Steve gives an insight into how they’re preparing for commercialization of their therapies within China, the affect COVID-19 has had on these partnerships, and how regulatory restrictions and language barriers can present a challenge in this area.

    Hosted on Acast. See acast.com/privacy for more information.

    29 min
  • To know COVID-19 is to know medicine
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr. RJ Tesi, CEO of INmune Bio about its clinical program that seeks to determine whether its existing TNF inhibitors can be repurposed to prevents complications of cytokine storm caused by COVID-19. Dr. Tesi gives solemn insight into trial design, endpoint selection, FDA application as well explaining how INmune is “messing” with the pathology of COVID-19, not only to treat its symptoms but to treat the disease itself. Dr. Tesi takes us through the evolving landscape of secondary complications caused by COVID-19 and leaves us with the anecdote that many in the industry are beginning to understand; “to know COVID-19 is to know medicine."

    Hosted on Acast. See acast.com/privacy for more information.

    42 min
  • Creating a collaborative toolbox to fight COVID-19
    In this episode of Conversations in Healthcare, Mike Ward talks to Werner Lanthaler, CEO of Evotec, about how COVID-19 is bringing pharma leaders together and giving them collaborative momentum. Dr. Lanthaler is a co-founding member of COVID R&D, a global pharma industry initiative that has come together to rapidly respond to the pandemic. Together they are fast-tracking learnings and protocols to create a toolbox that can accelerate activities like clinical trials, re-purposing compounds and data sharing to address the crisis faster. COVID-19 has brought barriers down and truly brought the healthcare industry together, but could this forced synergy and learning be used to accelerate treatment creation in the future?


    Hosted on Acast. See acast.com/privacy for more information.

    34 min
  • Wuhan experience shapes the new normal for healthcare

    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Christian Hogg, CEO of Hutchison China MediTech about how the organisation has tackled the impacts of COVID-19 on business globally. Christian gives us a month-by-month account from January to May of how they mitigated disruption and moved to a place of “new normal”, most notably within business activities related to commercial operations and getting vital medication to patients on clinical trials. With China slightly ahead of the pandemic curve from a timing perspective, what takeaways can the rest of the world utilise to ensure quicker recovery to the business of healthcare?



    Hosted on Acast. See acast.com/privacy for more information.

    28 min
  • Impact of COVID-19 on the development of CAR T-cell therapies
    In this episode of Conversations in healthcare, Mike Ward, Global Head of Thought Leadership talks to Dana Gheorghe, Ph.D, Associate Director, Oncology, about the impact COVID-19 is having on treatment for already available CAR T-cell therapies as well as those being developed. Dana gives us the lay of the land in an area where there is scarcity of information that is frequently changing. Dana covers how patients are being prioritised according to risk and need at this time and the challenges of getting high risk patient profiles much needed treatments. She also discusses the various country and region-specific conditions that are being put in place to allow treatment and trials to continue, however, many existing trials and read outs have been delayed despite and new trials completely suspended.


    Hosted on Acast. See acast.com/privacy for more information.

    27 min
  • Pivoting a product launch during the pandemic
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva for COVID-19 research. Learn more in the full episode.

    Hosted on Acast. See acast.com/privacy for more information.

    36 min

About Conversations in Healthcare

From the publisher's feed

Clarivate Conversations in Healthcare is a collection of candid interviews with key leaders and experts. Veteran industry journalist Mike Ward explores business challenges and opportunities the…